Nutriband Inc.

NASDAQ:NTRB

Biotechnology

Healthcare
$4.82 +22.32%

+$0.85 today

Market cap
$58.59M
Beta
1.97
P/E (TTM)
-1.8
EPS (TTM)
-$0.66
52W Low $2.80High $8.63

Volume 0.03M

Average 0.01M

NTRB Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Nutriband Inc.NASDAQ: NTRB

Revenue · Q1 FY2026 · quarter ended Apr 2026

Revenue declines year over year

Q1 FY2026 revenue of $433.4K fell 35.1% year over year, behind the -24.8% change in trailing-twelve-month revenue. Sequentially, it rose 8.2% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $95.41M (+4584.7%) for the fiscal year ending Jan 2027, a step up from the -4.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
$433.4K+8.2% QoQ
Last fiscal yearJan 2026
$2.04M-4.8% YoY
LTMApr 2026
$1.8M-24.8% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.1%-28.5%+6.5 pp
1 year-4.8%+4584.7%+4589.5 pp
3-year CAGR-0.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
2.04M USD
Year-over-year change
-4.8%
4-year CAGR
+9.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How NTRB compares with its peers on the latest reported figures

  • NTRB's LTM Apr 2026 revenue of $1.8M is the 3rd highest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of -24.8% is the lowest of 3, against a peer median of +60.6%.
  • Over three fiscal years its annual growth of -0.7% compares with a peer median of -6.2%.
NTRB Competitors Peer median
Revenue for NTRB and competitors
Company Period LTM YoY 3-year CAGR
FBIOFortress Biotech, Inc.LTM Mar 2026$66.16M +14.5%-5.8%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$9.14M +106.7%-8.6%
NTRBNutriband Inc.LTM Apr 2026$1.8M -24.8%-0.7%
ADAGAdagene Inc.LTM Jun 2024$815.75K —-6.2%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 ——
XBITXBiotech Inc.LTM Mar 2026$0 ——
GANXGain Therapeutics, Inc.LTM Mar 2026$0 ——
ACETAdicet Bio, Inc.LTM Mar 2026$0 ——
Peer median (excluding NTRB) $0+60.6%-6.2%

Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Jan 2024
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.42M2.08M2.09M2.14M2.04M
Cost of Revenue917.84K1.33M1.22M1.44M1.47M
Gross Profit504.31K750.41K862.11K699.3K566.31K
Gross Margin35.5%36.1%41.3%32.7%27.8%
Research & Development411.38K982.23K1.96M3.12M1.89M
Selling, General & Admin4.02M3.92M3.77M4.27M6.99M
Operating Expenses4.43M4.9M5.73M7.39M8.88M
Depreciation & Amortization318.26K368.96K287.72K285.05K193.8K
EBITDA(5.74M)(4.11M)(5.12M)(10.18M)(8.01M)
EBITDA Margin-403.6%-197.5%-245.6%-475.5%-393.5%
Operating Income(3.93M)(4.15M)(4.87M)(6.69M)(8.32M)
Operating Margin-276.3%-199.5%-233.6%-312.6%-408.4%
Interest Income0016.85K191.67K0
Interest Expense118.42K8.29K75.82K21.41K22.54K
Other Income / Expenses(2.25M)(335.62K)(613.39K)(3.79M)88.33K
Income Before Tax(6.18M)(4.48M)(5.49M)(10.48M)(8.23M)
Pre-Tax Margin-434.3%-215.6%-263.0%-489.9%-404.1%
Income Tax Expense00000
Net Income(8.42M)(4.81M)(5.49M)(10.48M)(8.23M)
Net Margin-592.2%-231.3%-263.0%-489.9%-404.1%
EPS (Basic)(1.06)(0.57)(0.69)(0.99)(2.58)
EPS (Diluted)(1.06)(0.57)(0.69)(0.99)(2.58)
Weighted Avg Shares7.93M8.46M7.95M10.61M11.64M
Weighted Avg Shares (Diluted)7.93M8.46M7.95M10.61M11.64M

Nutriband Inc.

NASDAQ:NTRB

Intrinsic Alpha fair value

Locked

Current Price

$4.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.